Black Rock Inc. Instil Bio, Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.4 - $0.63 $34,195 - $53,858	85,489 Added 6.72%	1,357,647 $583,000
Q2 2023 Aug 11, 2023	SELL	$0.51 - $0.67 $1.68 Million - $2.21 Million	-3,297,512 Reduced 72.16%	1,272,158 $699,000
Q1 2023 May 12, 2023	SELL	$0.6 - $0.91 $102,841 - $155,975	-171,402 Reduced 3.62%	4,569,670 $3.02 Million
Q4 2022 Feb 13, 2023	BUY	$0.48 - $5.33 $55,839 - $620,054	116,333 Added 2.52%	4,741,072 $2.99 Million
Q3 2022 Nov 14, 2022	BUY	$4.65 - $7.37 $1.97 Million - $3.13 Million	424,706 Added 10.11%	4,624,739 $22.4 Million
Q2 2022 Aug 12, 2022	BUY	$4.21 - $11.15 $3.53 Million - $9.36 Million	839,031 Added 24.96%	4,200,033 $19.4 Million
Q1 2022 May 12, 2022	BUY	$8.48 - $18.1 $331,237 - $707,004	39,061 Added 1.18%	3,361,002 $36.1 Million
Q4 2021 Feb 10, 2022	BUY	$15.37 - $22.5 $37.6 Million - $55 Million	2,445,958 Added 279.22%	3,321,941 $56.8 Million
Q3 2021 Nov 09, 2021	BUY	$15.05 - $23.28 $611,737 - $946,262	40,647 Added 4.87%	875,983 $15.7 Million
Q2 2021 Aug 11, 2021	BUY	$15.31 - $24.63 $12.8 Million - $20.6 Million	835,336 New	835,336 $16.1 Million

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $2.67B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.